Study of interactions between the nervous system and immunity offers insights into the pathogenesis of Parkinson's disease (PD) and potential therapeutic strategies for neurodegenerative diseases. Studies on rodents have revealed regulatory mechanisms of microglial activation and T lymphocyte recruitment in PD. However, the mechanisms underlying chronic T lymphocyte infiltration into the brain after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injection into a non-human primate (NHP) model of PD remain unknown. This study aimed to investigate changes in serum RANTES (regulated on activation, normal T cell expression and secretion) and analyze the chronic infiltration of T lymphocytes into the brain and microglia activation in NHPs at 48 weeks post-MPTP administration. We found selective and local chronic infiltration of CD4+ and CD8+ T lymphocytes, loss of dopaminergic neurons, dopamine transporter expression, chronic normalization of RANTES in the peripheral blood, and altered microglial morphology at 48 weeks after MPTP injection. This study confirms the involvement of CD4+ and CD8+ T lymphocyte infiltration in MPTP-induced NHP models of PD. Additionally, we corroborated previous findings regarding the mechanisms of T lymphocyteinduced neurodegeneration. The findings of chronic infiltration of T lymphocytes in our NHP model of PD provide novel insights into PD pathogenesis and the development of preventive and therapeutic agents. Recent studies have led to the development of a stable chronic MPTP-NHP model (Potts LF et al., 2014;Seo J et al., 2019); however, T lymphocyte infiltration into the brain during the chronic phase after MPTP injection in NHP models remains unclear. We believe that a better understanding of this Jensen EC (2013), Quantitative analysis of histological staining and fluorescence using ImageJ. Anat Rec (Hoboken) 296:378-381. Kalia LV, Lang AE (2015), Parkinson's disease. The Lancet 386:896-912. Kannarkat GT, Boss JM, Tansey MG (2013), The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis 3:493-514. Kavelaars A, Cobelens PM, Teunis MA, Heijnen CJ (2005), Changes in innate and acquired immune responses in mice with targeted deletion of the dopamine transporter gene. J Neuroimmunol 161:162-Saline Weeks after MPTP administration Baseline 8 16 24 32 40 48 Highlights  Brains of non-human primates induced by with MPTP showed chronic infiltration of T-cells  T-cells were observed in close proximity to dopaminergic neurons of the non-human primates Parkinson's disease model  DAT expression was found on infiltrated CD4+ and CD8+ T-cells  Chronic normalization of serum RANTES was observed in non-human primates after MPTP injection  Altered microglial morphology was found in the chronic phase after MPTP injection
Introduction
Parkinson's disease (PD) is a dopaminergic neurodegenerative disease characterized by movement disorders, including rigidity, bradykinesia, akinesia, tremors, and postural instability (Kalia LV and Lang AE, 2015; Poewe W et al., 2017; Vila M and Przedborski S, 2004) . Despite the immune privilege of the brain, previous reports have shown that interactions between the nervous system and immune function are associated with the pathogenesis of neurodegenerative diseases and the therapeutic strategies used to treat them (Ferretti MT et al., 2016; Korn T and Kallies A, 2017; Liblau RS et al., 2013; Pacheco R et al., 2014) .
Recent studies have shown that adaptive immunity and T lymphocyte activation are related to PD pathogenesis, including nigrostriatal neurodegeneration (Chen Z et al., 2018; De Virgilio A et al., 2016; Gendelman HE et al., 2017; Hirsch EC et al., 2012; Kannarkat GT et al., 2013; Mackie P et al., 2018; Mosley RL et al., 2012; Qian L et al., 2010) . Research on patients with PD has reported that blood, cerebrospinal fluid (CSF), and post-mortem brain tissue evinced the occurrence of long-term T lymphocyte infiltration (Baba Y et al., 2005; Bas J et al., 2001; Brochard V et al., 2009; Stevens CH et al., 2012; Tang P et al., 2014) . Additionally, the relevance of peripheral inflammation and CNS neurodegeneration in patients with PD was recently studied (Haghshomar M et al., 2019) . Genetic studies have confirmed that T lymphocytes that recognize alpha-synuclein of patients with PD induce the degeneration of nigral dopaminergic neurons (Benner EJ et al., 2008; Sulzer D et al., 2017) .
Furthermore, a recent in-vitro study confirmed T lymphocyte-induced neuronal degeneration in a patient with PD using an autologous induced pluripotent stem cell (iPSC)-based model (Sommer A et al., 2018) . Moreover, the severity of motor dysfunction in patients with PD significantly correlates with dopaminergic receptors on peripheral T lymphocytes (Kustrimovic N et al., 2016) , and T lymphocytes were associated with levels of the chemokine, RANTES (regulated on activation, normal T cell expression and secretion), in the serum (Tang P, et al., 2014) .
Animal PD models have revealed the infiltration of T lymphocytes in the acute or subacute phase after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration (Brochard V, et al., 2009; Chandra G et al., 2016; Martin HL et al., 2016; Reynolds AD et al., 2010) . The infiltration of CD4+ and CD8+ T lymphocytes into the substantia nigra of MPTP-induced non-human primate (NHP) models is observed at 1 month after MPTP administration (Roy A et al., 2015) . In addition, recent studies have reported that RANTES-associated infiltration of T lymphocytes plays an important role in driving persistent nigrostriatal pathologies in rodent models (Chandra G, et al., 2016; Chandra G et al., 2017) . These phenomena are supported by a study that reported that the knockout mice for major histocompatibility complex (MHC) class II, which present as endocytosed antigens to CD4+ lymphocytes, are resistant to MPTP toxicity (Martin HL, et al., 2016) .
The MPTP-NHP model is widely used to study PD because it exhibits clinical and pathological signs that are similar to those that are indicative of PD in humans (Porras G et al., 2012) . phenomenon will help identify the neuropathological mechanisms underlying PD in humans.
The role of dopamine transporter (DAT) in the expression of infiltrated T lymphocytes in brain parenchyma after MPTP injection also remains unclear. DAT is a well-known marker of dopaminergic neurons. DAT regulates intracellular and extracellular levels of dopamine in the basal ganglia via reabsorption expression. DAT is also expressed by peripheral lymphocytes, monocytes, and macrophages, and DAT-knockout mice reportedly exhibit changes of innate and acquired immunity (Kavelaars A et al., 2005) . In addition, the DAT-regulated communication between the peripheral dopamine system, which is comprised of immune cells, and the central dopamine system may play a key role in PD pathogenesis or progression (Mackie P, et al., 2018) .
This study investigated changes in serum RANTES and analyzed the chronic infiltration of T lymphocytes into the brain, DAT expression on infiltrated T lymphocytes, and microglia activation in NHPs at 48 weeks post-MPTP administration.
Experimental Procedures

Experimental animals and MPTP administration
We used eight adult female cynomolgus monkeys (Macaca fascicularis), which have been used to develop chronic Parkinsonian NHP models in previous studies (Seo J, et al., 2019) . The monkeys originated from the Zhaoqing Laboratory Animal Research Centre (Guangdong Province, China) and were maintained in individual indoor cages at the National Primate Research Center at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) as reported previously (Lee Y et al., 2014; Seo J, et al., 2019; Yeo HG et al., 2015) . Five monkeys were injected with MPTP (C1, C2, C3, C4, and C5), and three monkeys were injected with saline (C7, C8, and C9). The experimental design for MPTP administration (0.2 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) has been reported previously (Seo J, et al., 2019) ; an outline of the design is presented in Table 1 . Briefly, MPTP was dissolved in saline and injected intramuscularly into the left femoral region. The total dose of MPTP was commensurate with each individual animal's behavioral quantification. 
Parkinsonian behavior assessment and global activity
The behavior of the monkeys was evaluated using the Kurlan scale (Imbert C et al., 2000; Kurlan R et al., 1991; Seo J, et al., 2019) and global activity (Smart 3.0, Panlab S.L., Barcelona, Spain) via analysis of video recordings that were conducted for a total duration of 240 min. The Kurlan scale rates the following 10 parkinsonian motor symptoms: facial expression (0-3); resting tremor (0-3); action or intention tremor (0-3); posture (0-2); gait (0-3); bradykinesia (0-4); balance coordination (0-3); gross motor skills of upper limb (0-3) and lower limb (0-3); and defense reaction (0-2). To prevent subjective biases, the evaluation was performed in 5 min periods every 60 min by three trained examiners who were blind to the experimental design. Global activity has been described in our previous study (Seo J, et al., 2019) . Briefly, this software reflects quantitative changes in movements by counting the rates of change of all pixels between sequentially captured video images that contain 240 min of recordings for each experimental animal.
Blood preparation and analysis
Approximately 3 mL of whole blood was collected from the left femoral vein of deeply anesthetized animals. The blood samples were then transferred to an EDTA tube for hematological examination and a heparin tube for biochemical examination and Luminex assay. The hematological examination was performed using Hemavet 950FS (Drew Scientific, Dallas, USA). After the samples were centrifuged at 3000 g for 10 min to obtain plasma, the biochemical examination was performed with a FUJI DRI-CHEM 7000i automated clinical chemistry analyzer (FUJIFILM, Tokyo, Japan).
Luminex assay
Whole plasma was analyzed for the expression of RANTES using a MILLIPLEX® MAP nonhuman primate cytokine magnetic bead panel kit (EMD Millipore). Data were acquired using the Luminex-100TM instrument (Luminex, Ausitn, TX, USA) and analyzed using MasterPlex QT 2010 (mIRAIbIO, Hitachi, CA, USA).
Tissue preparation
Three MPTP-injected (C1, C2, C3) and three saline-injected (C7, C8, C9) monkeys were used in the tissue preparation analysis. The two remaining monkeys in the MPTP-injected group were used in a different behavioral experiment. The monkeys were deeply anesthetized with an intramuscular injection of ketamine (1 mg/kg) at 48 weeks after the first MPTP administration; then, they were transcardially perfused with 400 mL of 100 mM phosphate-buffered saline (PBS) as reported previously (Seo J, et al., 2019) . Whole brains were removed from the skull, washed in cold PBS, and bilaterally separated. The left hemispheres were post-fixed with 4% paraformaldehyde and incubated in a 30% sucrose solution at 4°C for immunohistochemical staining, and the right hemispheres were dissected into 4-mm thick slices, snap-frozen, and stored at −80°C for immunoblotting.
Immunohistochemistry and immunofluorescence
The left hemispheres of the brains were sectioned into 30-μm thick slices using a cryostat in the coronal plane (Leica Biosystems Table S1 ). The appropriate biotinylated anti-mouse, anti-goat, or anti-rat IgG antibodies (1:200, Vector Laboratories) were incubated for 2 h at room temperature. Staining was visualized using the ABC method (PK-6100, Vector Laboratories) with 3,3'-diaminobenzidine (DAB) as the peroxidase substrate. For the multiple staining required for light microscopy, the sections were incubated with anti-TH (1:1000, AB152, Merck Millipore) antibody at 4°C overnight after DAB staining using the anti-CD4 and anti-CD8 antibodies, and were subsequently incubated with horseradish peroxidase conjugated anti-rabbit IgG antibodies (1:200, Vector Laboratories) for 2 h at room temperature. Staining was visualized using the V-VIP (purple precipitate, Vector Laboratories) method (Lanciego JL and Gimenez-Amaya JM, 1999; Lanciego JL et al., 1997) . For immunofluorescence staining, the tissue sections were incubated with anti-TH (1:1000, AB152, Merck Millipore), anti-DAT
(1:1000, MAB369, Merck Millipore), anti-CD4 (1:1000, 317204, Biolegend), and anti-CD8 (1:1000, 344702, Biolegend) antibodies at 4°C overnight. Next, the sections were incubated with the appropriate AlexaFluor anti-mouse, anti-rabbit, or anti-rat (1:200, Invitrogen) secondary antibodies for 2 h at room temperature. DAPI staining was performed to detect the nuclei using mounting medium with DAPI (VECTASHIELD, H-1500) before covering the cover glass.
Imaging analysis
Sections were analyzed using light digital microscopy (Magnified 200×, Precipoint M8, PreciPoint, Germany). The regions of interest were segmented using a reference region from a previous study (Lanciego JL and Vazquez A, 2012; Martin RF and Bowden DM, 1996; Mounayar S et al., 2007) . The anterior commissure was used as an anatomical landmark for segmentation of the anterior and posterior striatum (Ballanger B et al., 2013; Seo J, et al., 2019) . The optical density (OD) of immunoreactivity in the regions of interest was measured using image analysis software (Jensen EC, 2013). To count T-lymphocytes, the total numbers of positive signals in all regions of interest (i.e., the putamen, caudate of the striatum, and substantia nigra) were divided by the total number of regions using a mouse click method in the software (ViewPoint, PreciPoint, Germany). The results were presented as the number of cells per square millimeter unit. Immunofluorescent images were acquired using the LSM-710 confocal microscope (Magnified 630x Carl Zeiss, Jena, Germany).
Western immunoblot analysis
The tissues were harvested from the putamen, caudate of the striatum, and substantia nigra using punches on 4 mm thick slices. Brain lysates were prepared using PRO-PREP protein extraction solution (Intron Biotechnology, Sungnam, Korea). Equal amounts of protein were separated by electrophoresis on 12% SDS-PAGE and transferred onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked by incubation with a blocking buffer (Sigma Aldrich, St.
Louis, MO, USA) and incubated with primary antibodies overnight at 4°C. The following primary antibodies were used: anti-Iba1 (ab108539, Abcam), anti-GFAP (Ab5804, Sigma Aldrich), and anti-β-actin (a5316, Sigma Aldrich). Membranes were washed with TBST and incubated with horseradish peroxidase-conjugated secondary antibodies (Thermo Scientific) at room temperature for 1 h. After removal of excess antibodies by TBST washing, specific binding was detected using a chemiluminescence detection system (Thermo Scientific) according to the manufacturer's instructions.
Statistical analysis
Statistical analyses were performed using the Statistical Package for the Social Sciences for Windows, Version, 18.0 (SPSS Inc., Chicago, IL). Differences in Parkinsonian behavior scores, global activity, and RANTES expression were analyzed at baseline, 8, 16, 24, 32, 48 weeks after MPTP injection using a repeated-measures ANOVA. Differences in the OD of immunoreactivity, RANTES expression, cell counts, and western blot analysis results between the saline-and MPTP-injected groups were performed using a one-tailed Student's t-test. Data are expressed as means ± standard deviation. P <0.05 was considered statistically significant.
Results
Effect of MPTP administration on dopaminergic neurons and behavioral symptoms
To validate the loss of dopaminergic neurons in the basal ganglia following MPTP administration, we performed immunohistochemistry using anti-TH and anti-DAT antibodies at 48 weeks after MPTP administration. TH and DAT OD measurements were recorded in the anterior and posterior of the striatum and substantia nigra. TH and DAT immunoreactivities were significantly reduced following MPTP administration in all striatal and substantia nigra regions; however, TH immunoreactivity was not significantly reduced in the ventral striatum (Fig. 1) . The number of TH+ positive cells was significantly decreased in the substantia nigra of MPTP-injected monkeys in comparison with saline-injected monkeys (Fig. 1C ). The progression of dopaminergic cell death and behavioral evaluations have been described in detail by a previous report (Seo J, et al., 2019) . Briefly, quantitative analysis using the 18 F-FP-CIT binding potential of positron emission tomography showed that presynaptic DAT activity was significantly reduced in all sub-regions of the striatum at 8, 16, 24, 32, 40, and 48 weeks after MPTP injection in comparison with saline-injected monkeys ( Supplementary Fig. S1 ). According to the Parkinsonian behavior scores and global activity, MPTP administration caused continuous stable PD symptoms ( Supplementary Fig. S2 ). 
The infiltration of CD4+ and CD8+ T lymphocytes in the striatum and substantia nigra at 48 weeks after MPTP administration
To confirm the chronic infiltration of T lymphocytes into the brain after MPTP administration, immunohistochemistry was performed using anti-CD4 and anti-CD8 antibodies at 48 weeks after MPTP administration. The numbers of CD4+ and CD8+ cells in the MPTP injected group were significantly increased in all striatum and substantia nigra regions as compared with those in the saline injected group (Fig. 2 ). In addition, T lymphocytes were identified using the CD3 marker in the MPTP injected group ( Supplementary Fig. S3 ). The co-localization of T lymphocytes and TH neurons was visualized using DAB/VIP and immunofluorescence staining ( Fig. 3, 4) . A cluster of CD4+ and CD8+ cells were present in the proximity of TH+ cells in the substantia nigra of the MPTP injected group. The infiltrated CD4+ and CD8+ cells increased in the striatum and substantia nigra at 48 weeks after MPTP administration compared with the saline-injected group (Fig. 2, 3, 4) or in the cortical regions of either group (data not shown). 
Dopamine transporter (DAT) was expressed in T lymphocytes that infiltrated into the brain parenchyma
To observe the expression of DAT in T lymphocytes that infiltrated into the brain parenchyma, we performed immunohistochemistry and immunofluorescence using anti-CD4, anti-CD8, and anti-DAT antibodies at 48 weeks after MPTP administration. Lymphoid morphology was observed in magnified (×200) DAT stained images of the striatum and substantia nigra (Fig. 5A ). Although it was still difficult to make a clear conclusion, the colocalization of CD4+ and CD8+ T cells and DAT was confirmed in the substantia nigra (Fig. 5B) . Immunofluorescence-stained images represent CD4+ and CD8+ T lymphocytes (green) and DAT (red) in the substantia nigra of MPTP-injected monkeys. DAPI staining was performed to detect the nuclei (dark blue). Scale bars, 10 µm.
Change in plasma RANTES levels induced by MPTP administration
We measured changes in plasma RANTES levels after MPTP administration using the Luminex assay at different time points. RANTES significantly increased at 8 weeks after MPTP administration and normalized from 24-48 weeks after MPTP administration (Fig. 6) . Results from the hematological and biochemical examinations of the blood samples after MPTP administration revealed that there were no significant veterinary clinical side effects ( Supplementary Table S2 and S3). 
Effect of MPTP administration on microglia in the basal ganglia
To examine the microglia induced by MPTP administration, immunohistochemistry and western blotting were performed using anti-Iba1 at 48 weeks after MPTP administration. Microglia displayed a ramified and amoeboid morphology in the MPTP-injected group (Fig. 7) . The amoeboid morphology of microglia and accumulation of fat granules were preponderantly observed in the anterior striatum and substantia nigra of animals in the MPTP-injected group. Meanwhile, there were no significant changes in the expression of Iba1 protein in the putamen and caudate of the striatum between the MPTP-injected and saline-injected groups ( Supplementary Fig. S4 ). 
Discussion
Our study provides novel findings concerning the chronic infiltration of T lymphocytes in an NHP model of PD; specifically, we confirmed the chronic infiltration of T lymphocytes (40-80 cells/mm 2 , Fig. 2 ) into the brains of our NHP model. Similar to our observations, a previous study showed that the infiltration of T lymphocytes (1.2-0.2 cells/mm 2 ) was maintained in the postmortem human brains of patients with PD (Brochard V, et al., 2009 ). In previous research on the MPTPintoxicated hemi-parkinsonian rhesus monkey, the infiltration of CD4+ and CD8+ T cells (2000 cells/mm 2 ) was observed after 30 days of treatment (Roy A, et al., 2015) . In a study that used a rodent MPTP model, the infiltration of CD4+ T cells (7500 cells/mm 2 ) and CD8+ T cells (300 cells/mm 2 ) was reported at 7 days after the injection of MPTP (Chandra G, et al., 2016) . Furthermore, a prior study also observed a high level (2000 cells/mm 2 ) of CD4+ T cell infiltration at the acute peak and the minimum level (<100 cells/mm 2 ) of CD4+ T cell infiltration in the chronic phase of the MPTP mice model (Chandra G, et al., 2017) . Each finding was independently reported to be significant when compared with the values observed in control groups. When considered together, the aforementioned results indicate that the degree of infiltration decreases with the passage of time. In contrast to a previous study that showed more CD8+ T lymphocytes in the deep parenchyma situated far from the blood vessels than CD4+ T lymphocytes in the substantia nigra at 30 days after MPTP injection (Roy A, et al., 2015) , our study did not reveal any local differences in infiltration at 48 weeks after MPTP injection. In addition, we did not find any significant correlations between the number of MPTP injections and the level of infiltrated T lymphocytes in our MPTP-NHP model (data not shown).
We observed the physical proximity of CD4+ and CD8+ T lymphocytes and nigral dopaminergic neurons in our NHP model of PD in the chronic phase after MPTP administration (Fig. 3,   4 ). Although direct adhesion molecule analyses were not shown, these results support the results of previous studies that described the interactions between neurons and T lymphocytes in the nervous system. CD4+ T lymphocytes are directly responsible for neuronal damage and mediate the mechanisms of neuronal damage via distinct molecules produced by CD4+ T lymphocyte subsets (Liblau RS, et al., 2013) . While the role of T helper (Th) 17 CD4+ lymphocytes in PD has recently garnered interest, no conclusions have been reached (Storelli E et al., 2019) . The lymphocyte function-associated antigen-1 (LFA1) on Th17 lymphocyte interacts with intercellular adhesion molecules (ICAM) on MPP+ treated ventral mesencephalic neurons (Liu Z et al., 2017) . Further, interleukin (IL) 17 is produced by Th17 lymphocytes and mediates neuronal cell death via the activation of NFB in a PD autologous iPSC-based model (Sommer A, et al., 2018) . Furthermore, a recent study reported that the cytotoxic CD8+ T lymphocytes recognize antigenic peptides associated with MHC class I molecules through their specific T cell receptors (TCRs) in neurological diseases.
Additionally, CD8+ T lymphocytes release lytic granules and cytokines that induce apoptosis towards neuronal axons (Huse M et al., 2008; Liblau RS, et al., 2013; Medana IM et al., 2000) . Although the infiltration of T lymphocytes into the brains of patients with PD and rodent models has been consistently reported, comprehensive functional analyses of T lymphocytes remain insufficient. An unsuitable immunological analysis in the post-mortem brain specimens of patients or problems with PD recovery in the MPTP rodent model may account for this insufficiency. Therefore, further functional molecular biological studies using NHP models of PD are warranted.
We identified that DAT was expressed on CD4+ and CD8+ T lymphocytes that infiltrated into the brain parenchyma. This finding relates to the following recent hypothesis: T lymphocytes are dependent on central and peripheral dopaminergic systems (Sarkar C et al., 2010) . Although more direct evidence is needed, the expression of DAT on the infiltrated T lymphocytes suggests that T lymphocytes are capable of releasing dopamine or contribute to PD via other mechanisms that are involved in the dopamine receptor pathway (Mackie P, et al., 2018) . An increasing body of evidence indicates that changes in the expression of DAT in peripheral T lymphocytes of PD patients may be related to neuronal injury (Amenta F et al., 2001; Buttarelli FR et al., 2011) . A significant reduction of DAT immunoreactivity on peripheral T lymphocytes of PD patients was reported (Pellicano C et al., 2007) . A potential relationship between DAT levels on peripheral and central T lymphocytes can be used to clinically diagnose PD or inform therapeutic strategies that address the condition (Mackie P, et al., 2018) . This study found that DAT was selectively and locally expressed on infiltrated T lymphocytes in MPTP-induced NHP PD models. These findings suggest that the peripheral dopamine system may contribute to the modulation of development and maintenance of PD; however, more direct evidence is required to validate this conclusion. The identification of DAT expression on infiltrated T cells will serve as a foundation for further research on the chronic migration and homing of T lymphocytes.
RANTES (also known as CCL5) is a chemotactic cytokine or chemokine that is produced in glial cells, such as microglia, astrocytes, and oligodendrocytes, and induces the migration and homing of T lymphocytes in the substantia nigra of the brain after MPTP administration (Appay V and Rowland-Jones SL, 2001; Chandra G, et al., 2016; Roy A, et al., 2015) . In this study that included MPTP-induced NHP PD models, plasma RANTES protein levels peaked at 8 weeks after MPTP administration and normalized at 48 weeks after MPTP administration (Fig. 6) . Likewise, in MPTPinduced mouse PD models, serum RANTES protein levels and mRNA expression peaked at 1 day after MPTP injection and normalized at 30 days after MPTP injection in parallel with the infiltration level of CD4+ lymphocytes (Chandra G, et al., 2017) . However, in contrast with the chronic phase of the mouse model, both CD4+ and CD8+ T cells also significantly infiltrated without intraperitoneal supplementation of chemokines (Fig. 2) . Without analysis of the acute phase in MPTP-induced NHP PD models, it is difficult to discuss this discrepancy. Nevertheless, issues that involve the glymphatic system, peripheral inflammation, microenvironment of the primate, and lifespan of T lymphocytes in the substantia nigra of patients with PD may explain this discrepancy.
We have two hypotheses. First, the meningeal spaces in the glymphatic system may be involved in the chronic infiltration of T lymphocytes into the basal ganglia through blood vessels.
Studies have suggested that the glymphatic system is a source of immune cells in the brain (Chen Z, et al., 2018; Plog BA and Nedergaard M, 2018) . Specifically, studies have reported that activated T lymphocytes were increased in the CSF of patients with PD (Schroder JB et al., 2018) . In contrast, the levels of T lymphocytes in the peripheral blood of patients with PD decreased as PD progressed (Hu ZX et al., 2018) . Although the mechanism involving the infiltration of T lymphocytes through the blood vessels in PD remains unknown, studies that focus on other neurological disorder animal models, such as experimental allergic encephalomyelitis (EAE), may provide an insight into the mechanism of T lymphocyte infiltration into the brain parenchyma (Chen Z, et al., 2018) . In a previous study that included a rat model of EAE, the T lymphocytes infiltrated into the brain parenchyma through the CSF and the leptomeninges (Schlager C et al., 2016) . T lymphocytes can translocate from the arachnoid mater into the CSF and then to the brain parenchyma through the pia mater (Chen Z, et al., 2018) .
Therefore, the migration of T lymphocytes in the MPTP-induced NHP PD model may be initially induced by RANTES from the peripheral to glymphatic system, and then this may lead to chronic infiltration from the meningeal space. Our second hypothesis suggests that the RANTES-independent infiltration of T lymphocytes may be present during the chronic phase of the NHP PD model. RANTES
is the most important chemokine in the MPTP animal model that controls the migration of T lymphocytes (Chandra G, et al., 2016) . There is a strong correlation between the severity, duration of motor dysfunction, and levels of serum RANTES in patients with PD (Tang P, et al., 2014) . However, studies that have focused on PD human patients have demonstrated that the correlation between elevated serum RANTES and PD progression may be attributed to the peripheral inflammatory states, as well as the nigral inflammatory states (Reale M et al., 2009; Tang P, et al., 2014) . In addition, there is a recently increasing understanding that T lymphocyte migration is controlled through the molecular regulation of diverse chemokines (Gregor CE et al., 2017) . Although RANTES is secreted from glia cells in the brain parenchyma, further studies are needed to explain the correlation with elevated levels in blood. Further immunological studies that assess the interaction between microglial RANTES and PD symptoms in NHP models are also necessary. As a result, we carefully suppose that diverse chemokines may also be involved in T lymphocyte migration in the chronic phase of PD.
Similar to previous studies, our results revealed that the amoeboid morphology of microglia and accumulation of fat granules were preponderantly observed in the anterior striatum and substantia nigra of the MPTP-injected group (Fig. 7) . In previous studies, the species-dependent highly heterogeneous morphology of microglia has been investigated (Barcia C, 2013; Lecours C et al., 2018) . In the striatum of MPTP-injected NHPs, the amoeboid morphology of microglia, which is linked to active phagocytosis, is associated with the accumulation of fat granules, and this effect was reduced in the substantia nigra (Hurley SD et al., 2003) . Microglia in the brains of patients with PD and NHP models of PD are rapidly activated during the acute phase of dopaminergic degeneration and maintained during the chronic phase (Gerhard A et al., 2006; Vazquez-Claverie M et al., 2009) . In contrast, amoeboid microglia appeared in the substantia nigra and striatum, and microglial activation is transient and normalizes during the chronic phase in rodent PD models (Brochard V, et al., 2009; Chandra G, et al., 2017; Kurkowska-Jastrzebska I et al., 1999) .
The cross-talk between T lymphocytes and microglia reportedly influences the polarization of the immune response and has the potential to be a therapeutic strategy in PD (Baird JK et al., 2019) . The activated T lymphocytes can polarize microglia toward a pro-inflammatory or antiinflammatory state. A pro-inflammatory state can be induced by the interaction with Th1 or Th17 subtypes of CD4+ T cells that release inflammatory molecules, such as tumor necrosis factor α, IL-1β, IL-6, and nitric oxide synthase. An anti-inflammatory state is modulated by the presence of Th2 or regulatory T lymphocytes that produce several cytokines, including IL-4, IL-5, IL-10, and transforming growth factor β, and neuronal growth factors, such as brain-derived neurotrophic factor (Baird JK, et al., 2019) . Meanwhile, catecholaminergic neurons of the human substantia nigra reportedly become vulnerable to attack by cytotoxic CD8+ T cells due to pro-inflammatory factors that are released by activated microglia (Cebrian C et al., 2014) . Although our study did not demonstrate a direct correlation between chronic T lymphocyte infiltration and activated microglia in the brain parenchyma of the NHP model of PD, this relationship requires clarification by future research to establish a therapeutic strategy.
We also believe that there are species-dependent discrepancies in the progression of PD. It appears that microglial activation and infiltration of T lymphocytes in rodents would be more transient than that in primates after MPTP injection. The microenvironment in the primate brain has more structurally complicated mechanisms that are involved in PD progression than the microenvironment in rodent models (Grow DA et al., 2016) . Primate brains have higher neuronal densities and a smaller average neuronal size than the rodent brain, and the ratio of glial/neuronal cells is different between primates and rodents (Herculano-Houzel S et al., 2007) . Unlike rodents, dopaminergic neurons in NHPs contain neuromelanin that plays a pivotal role in buffering toxic insults or in modulating the vulnerability of dopaminergic neurons (Dehay B and Bezard E, 2019; Vila M et al., 2019) .
This study is limited in that we did not analyze the acute period after MPTP injection, T lymphocyte cytotoxicity, or the effect of DAT on T lymphocytes; however, none of these assessment could be performed in our NHP model of PD. Although we do not know whether acute or chronic T cell infiltration may directly or indirectly (including microglia activation) drive persistent nigrostriatal degeneration in the NHP-PD model, Th17 lymphocyte cytotoxicity in PD has been demonstrated by in-vitro and rodent experiments (Liu Z, et al., 2017) . Moreover, the potential of Th17 lymphocyte functional blocking with FDA-approved drugs, such as secukinumab, as a therapeutic strategy has been suggested (Sommer A, et al., 2018) . Further studies on NHP models of PD are needed to elucidate the nigrostriatal degeneration pathway and specific cytotoxic molecules that are induced by chronic T cell infiltration in order to clarify the neuropathological mechanisms underlying PD in humans.
This study confirms the involvement of CD4+ and CD8+ T lymphocyte infiltration in MPTPinduced NHP models of PD. Further, these findings reinforce those of previous studies that identified the mechanisms involved in T lymphocyte-induced neurodegeneration. The findings of chronic infiltration of T lymphocytes in our NHP model of PD provide novel insights into PD pathogenesis and the development of preventive and therapeutic agents.
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Supplementary Methods. Positron emission tomography (PET) imaging protocol
All positron emission tomography (PET) images were acquired using a PET/computed tomography (CT) scanner (nanoScan PET-CT, Mediso Ltd., Budapest, Hungary). [ 18 F] N-(3fluoropropyl)-2ß-carboxymethoxy-3ß-(4-iodophenyl) nortropane ( 18 F-FP-CIT) PET imaging was performed to evaluate the expression of the dopamine transporter (Kazumata K et al., 1998) . 18 F-FP-CIT was obtained from a commercial company (DuChemBio Co., Ltd., Daejeon, Korea). We intravenously injected 185 MBq 18F-FP-CIT in 1.5 mL saline via the saphenous vein after a CT that was conducted for attenuation correction. Concurrently, PET acquisition with a 400 × 400 matrix size in the list mode was performed for 120 min following a 39-frame dynamic sequence: 15 s × 8, 30 s × 6, 60 s × 5, 120 s × 5, 300 s × 10, and 600 s × 5. The images were reconstructed using a threedimensional ordered subsets expectation maximization algorithm (Tera-Tomo, Mediso Ltd., Hungary) and post-processed using syngo VG51C software (Siemens Medical Solutions, Erlangen, Germany)
to visualize the multiplanar fusion images. The reconstructed voxel values in each frame were reported in standard uptake value from body weight and corrected for radioactive decay to the time of injection; the voxel dimensions were 0.4 × 0.4 × 0.4 mm 3 . The final three frames corresponding to 90-120 min following injection were used for dynamic analysis as the specific striatal uptake reached the maximum value from baseline. Data are expressed as mean ± SEM of MPTP (n = 5) and saline (n = 3) injected groups. The blood samples of saline injected group were collected at 48 weeks after saline administration. WBC, white blood cell; NE, neutrophil; LY, lymphocyte; MO, monocyte; EO, eosinophil; BA, basophil; RBC, red blood cell; Hb, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; PLT, platelet; MPV, mean platelet volume.
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